Brazilian Organization Files Opposition to Gilead's Antiretroviral Patent Application in India
June 30, 2008
The Brazilian group Interdisciplinary AIDS Association, or ABIA, has joined Indian patient advocacy groups to oppose a patent application for Gilead Science's antiretroviral drug Tenofovir, saying that the patent would have a direct impact on Brazil's ability to produce and access affordable generic versions of the drug, India's Business Standard reports. Opponents of the patent say that the drug consists of a previously known compound and, therefore, cannot be patented under India's Patents Act.
Chavez said an estimated 31,000 HIV-positive people in Brazil are expected to receive Tenofovir, known generically as viread, through the country's national AIDS program by the end of 2008. According to The Hindu, the Brazilian government is buying the drug directly from Gilead at the negotiated price of $1,387 per patient annually, and the lowest-priced generic versions of the drug are available in the Indian domestic market for $158. Some Indian pharmaceutical companies in 2006 signed an agreement with Gilead enabling them to manufacture the drug, but preventing them from exporting it or its raw materials to some middle-income countries, including Brazil. If the patent is not granted in India, companies will be able to compete for the domestic market; however, only those that have not signed the agreement with Gilead will be able to export (Hiddleston, The Hindu, 6/27).
The Times of India reports that the patent offices in both India and Brazil will review the case in July (Raaj, Times of India, 6/27).
CDC Report on New HIV Cases Among MSM Shows Need to Continue Prevention, Treatment Efforts, Editorial Says
Program at St. Louis Children's Hospital Will Offer HIV Tests, Results to Patients Older Than 15 Without Parental Consent
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.